Trial finds monoclonal antibody therapy improves survival in cancer-associated hyper-inflammatory disorder
Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH)—a rare, aggressive hyperinflammatory condition—who were treated with the first-in-class monoclonal antibody, ELA026, ...
Dec 10, 2024
0
0